FarEye Launches Grow – A Game-changing Self-Serve Merchant Portal for Logistics Companies to Accelerate Customer Acquisition and Drive Growth
11.5.2023 17:00:00 EEST | Business Wire | Press release
FarEye today announced Grow, a solution for logistic companies to provide a modern-age experience to its customers. With a user-friendly interface, frictionless onboarding, automated booking, and seamless payments integration, Grow is set to empower logistics businesses to accelerate customer acquisition, improve customer satisfaction, and drive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005538/en/
Grow is a cutting-edge self-serve merchant portal designed to revolutionize the way logistics companies manage their shipping operations. (Photo: Business Wire)
With the parcel delivery market projected to hit $200 billion by 2026 and over tens of millions of shippers worldwide, it's clear that logistic companies have an unprecedented opportunity for growth. Every retailer and e-commerce company wants to offer home delivery but continues to struggle to find the right, modern-age logistics partner and are stuck with legacy ways of home delivery. Grow enables logistics companies to address this demand-supply gap.
"We are thrilled to launch Grow, which we believe will become an indispensable tool for logistics companies seeking to acquire new retailers and stay ahead of the competition," said Kushal Nahata, CEO of FarEye. "Our team has worked tirelessly to create a platform that unlocks the potential of thousands of logistic companies, and we are confident that Grow will transform the way logistics businesses interact with their customers and manage their day-to-day operations."
FarEye Grow is an easy way for merchants to self-serve, get quotes, create orders, generate labels, and manage transactions. It also offers shipment-level visibility and in-built exception management, enabling retailers and shippers to save time and effort, leading to increased customer satisfaction. In addition, automated invoice generation and payments with digital wallet capabilities allow logistic companies to reduce payment delays and improve cash flow. Grow is equipped with built-in plug-ins with major e-commerce platforms like Shopify and BigCommerce, allowing shippers to connect and start delivering quickly.
FarEye Grow is a part of the FarEye product portfolio that supports companies through the complete order-to-door delivery journey. It has products like Ship, Track, Route, Execute, Experience, Analyze, and now, Grow, which offers the following key benefits:
- Personalized portal for easy onboarding: Allows self-onboarding and complete order entry, get quotes, generate labels, real-time status updates, and proof of delivery on one platform.
- Track and trace visibility: Provides real-time track and trace visibility and address validation to merchants for booked orders.
- Scale with your merchants: Track merchants’ growth, run campaigns based on orders and transactions, and make recommendations for merchants to transact more for revenue and business growth.
- Booking order transparency: Self-service merchant order booking directly from the platform, this helps CEPs track revenue and reduce lost revenue.
- Digital wallet management: Offer customers purchase credit for their shipping needs. Provide complete visibility into all transactions, book and pay for shipments by multiple payment modes, including directly by wallet.
FarEye's Grow is the ultimate customer portal for CEP companies looking to streamline shipping operations, expand their customer network, and achieve sustainable growth in today's competitive industry. To learn more about the portal and how it can benefit your business, visit the FarEye website today.
About FarEye
FarEye’s Delivery Management platform turns deliveries into a competitive advantage. Retail, e-commerce and third-party logistics companies use FarEye’s unique combination of orchestration, real-time visibility, and branded customer experiences to simplify complex last-mile delivery logistics. The FarEye platform allows businesses to increase consumer loyalty and satisfaction, reduce costs and improve operational efficiencies. FarEye has 150+ customers across 30 countries and five offices globally. FarEye, First Choice for Last Mile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005538/en/
Contact information
PR Contact:
Bradford Peirce, Industry Strategy Executive, bradford.peirce@fareye.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom